LenioBio GmbH announces the appointment of Dr. Dorothee Ambrosius to LenioBio’s Scientific Advisory Board (SAB).
Dusseldorf, September 30, 2021– LenioBio GmbH, a German life science biotech offering a disruptive protein manufacturing technology, ALiCE®, announces the appointment of Dr. Dorothee Ambrosius to LenioBio’s Scientific Advisory Board.
“We are thrilled to have such an expert as Dr. Dorothee Ambrosius joining our SAB” said Dr. Ricarda Finnern, CSO of LenioBio. “Dr. Ambrosius brings years of experience in developing bioprocesses for manufacturing biopharmaceuticals”.
Dr. Ambrosius, a senior expert with over 30 years of experience in research and development of biopharmaceutical medical products, operates since 2020 as an independent Senior Advisor. The research, development, and production of innovative biological medicines to treat unmet medical needs and the application of cutting-edge technologies in process development have been the focus of her entire industrial career. She developed profound leadership and management skills along with business sense and held numerous management positions at three different global pharmaceutical companies.
She joined Boehringer Ingelheim in 2003 and held various management positions, including Director Downstream Development, Head Strategy for Biologicals and Senior Vice President Bioprocess & Pharmaceutical Development responsible for early-stage and late-stage process development heading a global organisation with more than 700 employees in Germany, Austria, US and China.
Dr. Ambrosius started her industrial career in 1989 as a group leader in Penzberg at the Roche Research Center for Large Molecules (formerly Boehringer Mannheim until 1996) in discovery and process research for Biologics.
Dorothee received her PhD in Biology from RWTH Aachen in 1989.
In addition to her industrial career, she has been a member of a university council, serves on various conference organizing committees, is a guest lecturer at KIT, and is a member of scientific advisory boards of biotech companies.
Dr. Ambrosius explains, “LenioBio’s technology platform has enormous potential to revolutionize the development and production of proteins and peptides for a wide variety of applications. I am very pleased to guide LenioBio and the ALiCE platform on the journey to industrial application”.